Survival Rate for aHUS with Prompt Eculizumab Treatment

Critical Treatment Timing and Infection Prevention

• Delays in initiating eculizumab treatment are associated with increased morbidity and mortality, emphasizing the need for treatment within hours of diagnosis, as recommended by Pharmacological Research 1, 2
• Mandatory infection prevention measures include quadrivalent meningococcal conjugate vaccine and meningococcal B vaccine, as well as long-term antimicrobial prophylaxis with penicillin, according to Pharmacological Research and supported by 1, 2, and 3, though 3 is from a less preferred source, the information is consistent with 1 and 2, thus: 1, 2